Anti-CD8A / CD8 alpha chain, clone MSVA-008R

Antibody in 1X PBS with 0.05% BSA, 0.05% sodium azide. CD8 alpha (CD8A) is a transmembrane glycoprotein expressed on cytotoxic T lymphocytes that functions as a co-receptor for T cell receptor signaling through interaction with MHC class I molecules. CD8A Antibody for IHC is widely used to detect and localize cytotoxic T cells within tissue sections, making it a critical immunohistochemistry marker for evaluating immune infiltration in both normal and cancer tissues. CD8A antibody, also referred to as CD8 alpha antibody or CD8 antigen antibody, is one of the most established markers for identifying tumor-infiltrating lymphocytes in FFPE specimens.CD8A belongs to the immunoglobulin superfamily and is localized to the cell membrane, where it forms heterodimers with CD8B or homodimers in specific immune subsets. In immunohistochemistry applications, CD8A staining produces clear membranous labeling of lymphocytes, enabling precise visualization of cytotoxic T cells within complex tissue architecture. This membranous staining pattern allows CD8A immunohistochemistry antibody detection to reliably distinguish infiltrating lymphocytes from surrounding epithelial cells, stromal compartments, and tumor cells, supporting accurate interpretation in pathology and research settings.CD8A Antibody for IHC is particularly important in immuno-oncology, where the density and spatial distribution of CD8-positive T cells are closely linked to prognosis and response to immunotherapy. Increased infiltration of CD8-positive lymphocytes within tumor regions is commonly associated with improved clinical outcomes and enhanced response to checkpoint blockade therapies. As a result, CD8 immunohistochemistry antibody staining is widely used to assess tumor immune contexture, characterize tumor-infiltrating lymphocytes, and support studies of immune activation, immune exclusion, and tumor-immune interactions across diverse cancer types.This recombinant rabbit monoclonal antibody, clone MSVA-008R, is optimized for immunohistochemistry and demonstrates strong performance in formalin-fixed, paraffin-embedded tissues. Validation using human tissue microarray (TMA) panels provides broad evidence of staining consistency and specificity across a wide range of normal and cancer tissues. In TMA-based immunohistochemistry analysis, CD8A staining reveals scattered cytotoxic T cells in most non-lymphoid tissues, with strong enrichment in lymphoid organs such as tonsil, lymph node, and spleen. In cancer tissues, variable densities of CD8-positive lymphocyte infiltration are observed, reflecting differences in tumor immune microenvironments and supporting the use of CD8A antibody for immune profiling studies.TMA validation is especially valuable for CD8A antibody performance assessment because it enables side-by-side comparison across dozens of tissue types under identical staining conditions. CD8A antibody staining in these arrays aligns with known biological distribution patterns, showing minimal background staining in non-immune cells and strong, specific membranous labeling of infiltrating lymphocytes. This level of cross-tissue validation supports reproducibility and confidence in immunohistochemistry results, particularly in studies requiring consistent detection across multiple tissue types.CD8A immunohistochemistry antibody staining is also widely used in spatial biology and multiplex IHC approaches, where understanding the localization of cytotoxic T cells relative to tumor cells, vasculature, and stromal compartments is critical. CD8A antibody enables visualization of immune cell positioning within tumor nests, invasive margins, and peritumoral regions, providing insight into immune accessibility and tumor immune evasion mechanisms. When used in combination with markers such as CD3 antibody, CD4 antibody, and PD-1 or PD-L1 antibodies, CD8A Antibody for IHC supports comprehensive characterization of immune composition and functional state within tissue microenvironments, making it a cornerstone reagent for immunohistochemistry-based immune analysis.This antibody is part of a broader selection of immune cell marker antibodies designed to support studies of T cell biology, immune infiltration, and tumor immunology, including application-specific CD8A antibody reagents for IHC, FACS, WB, and IF.This antibody is also part of a broader collection of IHC antibodies validated by tissue microarray analysis, supporting consistent staining across normal and cancer tissues.